Pumpkin Seed Oil Supplement Tested in People on Hemodialysis
Tests pumpkin seed oil supplement alongside usual care in adults receiving hemodialysis.
Plain-language title generated from the registry record
Registry title: Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients
Key facts
- Where
- Baghdad, IraqSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with end-stage kidney disease who have been on hemodialysis for more than 6 months and are medically stable.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- End-stage kidney disease on hemodialysis for more than 6 months, on a constant dialysis program. Stable, with no recent hospital stay for infection, heart problems or major surgery in the past 3 months.
- Earlier treatment
- No regular dietary supplements (such as omega-3 or antioxidants) in the month before the trial.
- Biomarker or test result
- Serum albumin of at least 3.0 g/dL. No active acute infection.
Main reasons for not taking part
- Autoimmune disease, liver disease, cancer or AIDS
- Diabetes
- Allergy to pumpkin seed oil
- Current use of lipid-lowering drugs, anticoagulants, immunosuppressants, corticosteroids or anti-inflammatory drugs
- Pregnant or breastfeeding women
This trial only enrols participants on dialysis. The registry sentence this rests on: End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program.
Read by machine on 9 November 2026.
Where in Iraq
- Al-Karama Teaching Hospital, Hemodialysis CenterBaghdad, IraqTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Al-Mustansiriyah University
- Trial code
- NCT07710183
- Record updated
- 17 July 2026
- Original description
Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg/day plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, IraqRead full original descriptionShow less
Potential Role of Pumpkin Seed Oil as a Nutraceutical on the Clinical and Biochemical Outcomes in Hemodialysis Patients
Patients with end-stage renal disease (ESRD) on maintenance hemodialysis experience chronic systemic inflammation, oxidative stress, and dyslipidemia, which together drive much of the excess cardiovascular morbidity and mortality seen in this population. Pumpkin seed oil is a nutraceutical rich in polyunsaturated fatty acids, phytosterols,and tocopherols, with documented antioxidant, anti-inflammatory, and antihyperlipidemic properties in preclinical and limited clinical studies. This study investigates the potential role of pumpkin seed oil as a nutraceutical on the clinical and biochemical outcomes of hemodialysis patients. It is a randomized, open-label, prospective interventional study in which daily oral supplementation with pumpkin seed oil (1000 mg once daily) for 3 months is evaluated against usual care. Eighty-five participants will be assigned to either an intervention group (n=45, pumpkin seed oil 1000 mg/day plus usual care) or a control group (n=40, usual care only). The biochemical outcomes assessed are changes in serum interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), lipid profile, malondialdehyde (MDA), and superoxide dismutase (SOD) from baseline to the end of the 3-month follow-up period. The study is being conducted at the Hemodialysis Center, Al-Karama Teaching Hospital, Iraq
Inclusion: End-stage renal disease (ESRD) on hemodialysis for more than 6 months, on a constant dialysis program; Hemodynamically stable (no recent hospitalization for infections, cardiovascular events, or major surgery within the past 3 months); No active acute infections; Serum albumin ≥ 3.0 g/dL.
Exclusion: Regular intake of dietary supplements (e.g., omega-3, antioxidants) for at least one month prior to enrollment; Current use of immunosuppressants, corticosteroids, or anti-inflammatory drugs; Autoimmune disease, liver disease, cancer, or acquired immunodeficiency syndrome (AIDS); Known sensitivity/allergy to pumpkin seed oil; Diabetes mellitus; Current use of lipid-lowering agents; Current use of anticoagulants (warfarin, direct oral anticoagulants); Pregnant or breastfeeding women; Residual kidney function (urine output > 200 mL/day).